Merck Defended By Sen. Hatch During Vioxx Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck behaved "responsibly" in its handling of the COX-2 inhibitor Vioxx (rofecoxib), Sen. Orrin Hatch (R-Utah) said near the conclusion of a Nov. 18 Senate Finance Committee hearing on the withdrawn COX-2 inhibitor